WRN-108

1. WRN-108 decreases DNA damage response in human cells.

   “reduced senescence-associated markers, G-quadruplex accumulation, and γH2AX signaling”

   Cellsin WS patient-derived fibroblasts

   Development of an exon 27-skipping antisense oligonucleotide as a targeted therapy for refractory skin ulcers in Werner syndrome

   Molecular therapy. Nucleic acids·Apr 6, 2026

More on DNA damage response

1. WRN-108 decreases cellular senescence in human cells.

   “reduced senescence-associated markers, G-quadruplex accumulation, and γH2AX signaling”

   Cellsin WS patient-derived fibroblasts

   Development of an exon 27-skipping antisense oligonucleotide as a targeted therapy for refractory skin ulcers in Werner syndrome

   Molecular therapy. Nucleic acids·Apr 6, 2026

More on Cellular senescence

1. WRN-108 improves cell proliferation in human cells.

   “Treatment improved cell proliferation”

   Cellsin WS patient-derived fibroblasts

   Development of an exon 27-skipping antisense oligonucleotide as a targeted therapy for refractory skin ulcers in Werner syndrome

   Molecular therapy. Nucleic acids·Apr 6, 2026

1. WRN-108 increases wrn in human cells.

   “restored WRN protein expression, and re-established its nuclear localization”

   Cellsin WS patient-derived fibroblasts

   Development of an exon 27-skipping antisense oligonucleotide as a targeted therapy for refractory skin ulcers in Werner syndrome

   Molecular therapy. Nucleic acids·Apr 6, 2026

More on wrn